Alpha-interferon in superficial XXXX : a Northern California Oncology Group Study.

@entity1 @entity137 @entity2735 @entity5 @entity150 @entity1141
Thirty-five @entity1 with superficial transitional @entity150 were treated intravesically with escalating doses of recombinant alpha-2-interferon administered weekly for 8 weeks. Of the 19 @entity1 with high-grade intraepithelial @entity5 (17 @entity2735 [ @entity2735 ], two severe @entity1141 , all cytology positive), six (32%) had complete resolution of all histologic and cytologic evidence of disease (complete response). An additional three @entity1 (16%) had complete resolution of @entity2735 , but the interval appearance of a low-grade transitional cell @entity5 . Five (26%) had a partial response (complete resolution of all evidence of @entity2735 on multiple bladder biopsies but persistently positive cytologic preparations). Sixteen @entity1 with recurrent @entity5 and extensive prior therapy were also treated. Four (25%) had a complete response. Twenty-three of the 35 @entity1 had prior intravesical therapy. Seven of the 23 (30%) @entity1 with prior intravesical chemotherapy or immunotherapy had a complete or partial response to interferon, while eight of the 12 @entity1 (67%) without prior intravesical treatment responded. These responses were achieved with minimal local and systemic @entity137 . Of the ten complete responders, five remain in continuous unmaintained remission for 18+ to 37+ months. Intracavitary alpha-2-interferon is an effective new treatment for some @entity1 with @entity150 .
